X T L Biopharmaceuticals Ltd
TASE:XTLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Manhattan Associates Inc
XMUN:MHT
|
US |
X T L Biopharmaceuticals Ltd
Research & Development
X T L Biopharmaceuticals Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
X
|
X T L Biopharmaceuticals Ltd
TASE:XTLB
|
Research & Development
-$40k
|
CAGR 3-Years
59%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Research & Development
-$12.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Research & Development
-$9.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Research & Development
-$67.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Research & Development
-$5.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Research & Development
-$15.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
X T L Biopharmaceuticals Ltd
Glance View
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
See Also
What is X T L Biopharmaceuticals Ltd's Research & Development?
Research & Development
-40k
USD
Based on the financial report for Dec 31, 2018, X T L Biopharmaceuticals Ltd's Research & Development amounts to -40k USD.
What is X T L Biopharmaceuticals Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
18%
Over the last year, the Research & Development growth was 0%. The average annual Research & Development growth rates for X T L Biopharmaceuticals Ltd have been 59% over the past three years , 18% over the past five years .
